What happens next in GLP-1 — and when.

Get the briefing

What moved in the GLP‑1 field, in your inbox.

@glp1briefing

What changed › 2026-08-26

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

Detected 2026-08-26 in the trials record for tirzepatide, by comparing that day’s fetch against the previous one.

A completion date is the sponsor's estimate of when the main result will be in hand. ClinicalTrials.gov overwrites the old date when it moves, keeping no public history, so the previous value below exists nowhere else.

What changed

ChangeFieldValue
results date movedprimary_completion_date2028-12-312029-10-31

What the record says now

Status
Not yet recruiting
Phase
P2
Participants
55
Primary completion
2029-10-31
Sponsor
National Cancer Institute (NCI)

See tirzepatide · NCT07349641 · the source record.

The previous value above is not recoverable from the source. Both ClinicalTrials.gov and the FDA revise records in place, keeping no public history, which is why this site keeps its own.